Investor Relations

Company Overview

Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in this indication presents the highest chance of success with the greatest commercial opportunity.

Latest Presentation

Upcoming Events

November 14 – November 15, 2018

Jefferies 2018 London Healthcare Conference

Waldorf Hilton, London, UK
December 1 – December 4, 2018

60th Annual American Society of Hematology Annual Meeting & Exposition

San Diego Convention Center, San Diego, CA
January 17 – January 19, 2019

American Society of Clinical Oncology sponsored, Gastrointestinal Cancers Symposium 2019

Moscone West Building, San Francisco, CA
View All Events

Stock Information

Symbol

Nasdaq ONCY

Price

Change

Symbol

TSX ONC

Price

Change

Investor Relations

Michael Moore
Vice President Investor Relations and Corporate Communications
T: (403) 670-7377 Ext. 2
mmoore@oncolytics.ca